Mark Wildgust: Why Culture Drives Innovation in Oncology
Mark Wildgust/X

Mark Wildgust: Why Culture Drives Innovation in Oncology

Mark Wildgust, Vice President, Global Medical Affairs, Oncology at The Janssen Pharmaceutical Companies of Johnson and Johnson, shared on LinkedIn:

“Breakthroughs change outcomes. Culture changes what’s possible.

Time in New England this weekend reminded me that the most enduring progress isn’t born only from science – it’s born from the culture that sustains it.

Culture is the quiet force that shapes how we show up for one another:

  • How we listen with empathy.
  • How we challenge with curiosity.
  • How we support with conviction.

And just as culture sustains teams, restoration sustains individuals. Taking time to pause, reflect, and restore ourselves is not a luxury – it’s a necessity. Renewal fuels resilience, and resilience fuels the kind of culture where innovation thrives.

In oncology, the pace of discovery is extraordinary. But it’s the environment we create – one where teams feel empowered, patients remain our north star, and balance is valued -that transforms discovery into impact.

When culture inspires, innovation compounds. When culture uplifts, hope expands.

Science advances outcomes. Culture – and restoration – advance possibility.”